User profiles for Ahed Makhoul
Ahed MakhoulCleveland Clinic Foundation Verified email at ccf.org Cited by 58 |
BCOR and BCORL1 mutations in myelodysplastic syndromes (MDS): clonal architecture and impact on outcomes
…, A Advani, B Przychodzen, A Makhoul… - Leukemia & …, 2019 - Taylor & Francis
To the Editor, The myelodysplastic syndromes (MDS) are a heterogeneous group of
hematologic conditions characterized by dysplastic changes and ineffective hematopoiesis [1]. …
hematologic conditions characterized by dysplastic changes and ineffective hematopoiesis [1]. …
The role of palliative care in COVID-19.
D Sese, A Makhoul, L Hoeksema… - Cleveland Clinic Journal …, 2020 - europepmc.org
In light of the COVID-19 pandemic, many healthcare systems are experiencing an increased
demand for palliative care (PC). To meet this challenge, the PC team at Cleveland Clinic …
demand for palliative care (PC). To meet this challenge, the PC team at Cleveland Clinic …
[HTML][HTML] A personalized prediction model to risk stratify patients with acute myeloid leukemia (AML) using artificial intelligence
Background AML is a heterogeneous clonal disorder that is characterized by the accumulation
of complex genomic alterations that affect disease biology and outcomes. Despite …
of complex genomic alterations that affect disease biology and outcomes. Despite …
[HTML][HTML] A personalized prediction model to risk stratify patients with acute myeloid leukemia (AML)
AML is a heterogeneous clonal disorder that is characterized by the accumulation of complex
genomic abnormalities that impact disease biology and outcome. Despite significant …
genomic abnormalities that impact disease biology and outcome. Despite significant …
[HTML][HTML] Model heterogeneity in predicting outcomes of patients with myelodysplastic syndromes (MDS)
Background The outcome of MDS patients (pts) is heterogeneous, with some pts living for
years, while others die within a few months of diagnosis. Several prognostic models have …
years, while others die within a few months of diagnosis. Several prognostic models have …
Response Rates to Methylnaltrexone in Hospitalized Cancer Patients
…, F Fielding, R Lagman, A Makhoul… - American Journal of …, 2023 - journals.sagepub.com
Context: Methylnaltrexone is a peripherally-acting mu-opioid receptor antagonist studied in
both cancer and non-cancer patients with opioid-induced constipation (OIC), but mostly in …
both cancer and non-cancer patients with opioid-induced constipation (OIC), but mostly in …
Molecular dissection of normal karyotype acute myeloid leukemia.
7534 Background: Conventional cytogenetics remain one of the most important prognostic
factors in acute myeloid leukemia (AML), though 50-60% of patients (pts) have normal …
factors in acute myeloid leukemia (AML), though 50-60% of patients (pts) have normal …
Methylnaltrexone for Refractory Opioid-Induced Constipation in Hospitalized Cancer Patients—A Highly Effective Treatment (F415A)
…, F Fielding, RL Lee, A Makhoul… - Journal of Pain and …, 2021 - jpsmjournal.com
Methods We performed a single-center, retrospective chart review of all hospitalized, adult
patients with a cancer diagnosis who received methylnaltrexone from the palliative medicine …
patients with a cancer diagnosis who received methylnaltrexone from the palliative medicine …
[HTML][HTML] Molecular Characterization of Acute Myeloid Leukemia Patients with Normal Karyotype
Background Conventional cytogenetic classification remains one of the most important
prognostic factors in acute myeloid leukemia (AML). Approximately 50-60 % of patients (pts) with …
prognostic factors in acute myeloid leukemia (AML). Approximately 50-60 % of patients (pts) with …
[HTML][HTML] Patterns of Genomic Associations Can Define Acute Myeloid Leukemia (AML) Phenotype
AML can develop after an anteccedent myeloid malignancy (secondary AML [sAML]) or
arise de novo (pAML). Genome sequencing technologies have illuminated the complexity of …
arise de novo (pAML). Genome sequencing technologies have illuminated the complexity of …